Miller Steve

COO/Scientific Officer Miller sells 115,000 CPRX shares at $20.28; stock down 22.5% from 52-week high.

Miller Steve, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, sold 115,000 shares (9.8% reduction from 1,174,663 pre-transaction holdings) at $20.28 on 2025-08-26, generating $2.3M in proceeds. At current price of $20.38, the stock is -22.5% from its 52-week high of $26.31 and down -18.4% over the past 90 days. Across his prior 4 trades at CPRX specifically, only 1 of 4 sells registered a negative 90-day return (well-timed for sells), suggesting modest timing precision at this ticker. The company shows healthy fundamentals—$146.6M quarterly revenue, $52.1M net income, and 23.5% annual revenue growth with an 11.99 P/E—which contrasts with recent stock weakness and provides context for evaluating whether this sale represents conviction-driven exit or portfolio rebalancing against a broader market correction.

COO Steve Miller sells 50.0K CPRX shares at $21.93; stock now -8.2% from 52-week high amid 85.9% revenue growth.

Miller sold 50,000 shares (6.8% of his pre-transaction holdings) on 2024-12-10 at $21.93, reducing his stake from 737.0K to 687.0K shares. The company demonstrates strong fundamentals with $128.7M revenue in the latest quarter and annual revenue growth of +85.9%, combined with net income of $43.9M and a reasonable P/E of 18.31. However, the stock has declined 6.3% over the past 30 days and sits -8.2% below its 52-week high of $23.93, suggesting a pullback from recent peaks. Notably, Miller's prior three sales at CPRX all resulted in positive 90-day returns (ranging 1.1% to 3.0%), meaning the stock rose after each sale—a pattern of consistently poorly-timed exits that does not suggest prescient bearish conviction on this occasion either.

COO Steve Miller sells 150,000 shares at blended $20.35 for $3.1M; stock near 52-week high of $20.74

Steve Miller, Chief Operating & Scientific Officer, executed 3 separate sales totaling 150,000 shares for $3,052,900.00 on 2024-08-20 at prices ranging from $20.21 to $20.58 (blended average $20.35), reducing his holdings from 825,124 shares to 675,124 shares. The sale occurred while the stock trades at $20.74, near its 52-week high of $20.74, and follows a strong 18.1% gain over the prior 30 days and 30.7% gain over 90 days. Catalyst Pharmaceuticals is growing rapidly with annual revenue growth of 85.9% and trailing net income of $40,794,000.00 on quarterly revenue of $122,710,000.00, though the P/E of 36.39 reflects elevated valuation. The sale's magnitude (18.2% of pre-transaction holdings) at peak-range pricing during a period of sustained momentum warrants investor attention to ascertain whether this reflects the insider's current portfolio positioning or other factors.